Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma

被引：0
|
作者：
Demeter, J.
Balassa, K.
Domotor, M.
Egyed, M.
Gasztonyi, Z.
Aryab, H.
Gurzo, M.
Ivayi, J.
Klucsik, Zs.
Sreter, L.
Nagy, Zs.
机构：
[1] Semmelweis Univ, Sopron Hosp, Dept Med, Kaposvar, Hungary
[2] Kaposi Mor Teaching Hosp, Dept Internal Med, Kaposvar, Hungary
[3] Petz Aladar Hosp Gyor, Kecskemet, Hungary
[4] Dept Med 2, Kecskemet, Hungary
[5] Markusovsky Hosp, Dept Internal Med, Szombathely, Hungary
来源：
BLOOD REVIEWS | 2007年 / 21卷
关键词：
D O I：
10.1016/S0268-960X(07)70245-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S138 / S139
页数：2
相关论文
共 50 条
  • [21] Penetration of Yttrium-90-labeled ibritumomab tiuxetan (Zevalin™) into primary CNS lymphoma.
    Kiewe, Philipp
    Korfel, Agnieszka
    Maza, Sofiane
    Jahnke, Kristoph
    Munz, Dieter L.
    Thiel, Eckhard
    BLOOD, 2006, 108 (11) : 770A - 770A
  • [22] TREATMENT WITH YTTRIUM-90 (90Y)-IBRITUMOMAB TIUXETAN (ZEVALIN®) IN DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS
    Auger, S.
    Duny, Y.
    Daures, J. P.
    Quittet, P.
    HAEMATOLOGICA, 2014, 99 : 700 - 700
  • [23] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    Doyle, Catherine
    Smith, Johnna
    Bello, Celeste M.
    Sokol, Lubomir
    El-Haddad, Ghassan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [24] Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
    Kim, Moon Jin
    Lee, Gyeong-Won
    Seo, Jong Woo
    Kim, Hyun-Jung
    Lim, Sung-Nam
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1098 - 1101
  • [25] The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    Cheson, BD
    BIODRUGS, 2005, 19 (05) : 309 - 322
  • [26] High response rates for stage 1-II indolent B-cell lymphoma with yttrium-90 ibritumomab tiuxetan (Zevalin)
    Samaniego, F.
    Pro, B.
    Nunez, R.
    McLaughlin, P.
    Fanale, M.
    Kwak, L.
    Romaguera, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 208 - 208
  • [27] Healthcare professionals directly involved in the administration of Yttrium-90 ibritumomab tiuxetan (Zevalin®) receive minimal radiation exposure
    Wiseman, GA
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S457 - S457
  • [28] Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
    Moon Jin Kim
    Gyeong-Won Lee
    Jong Woo Seo
    Hyun-Jung Kim
    Sung-Nam Lim
    Cheolwon Suh
    Investigational New Drugs, 2011, 29 : 1098 - 1101
  • [29] Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience
    Moustafa, Muhamad Alhaj
    Parrondo, Ricardo
    Wiseman, Gregory
    Peterson, Jennifer
    Witzig, Thomas E.
    Tun, Han W.
    BLOOD, 2019, 134
  • [30] USE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN PATIENTS WITH CD20+ NHL: SINGLE CENTRE EXPERIENCE
    Alizadeh, H.
    Kristensen, J.
    Alam, A.
    Kumar, P.
    Mohamadiyah, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 528 - 528
12345